Pharmacokinetic evaluation of the aripiprazole (once-monthly) injection for the treatment of bipolar disorder

Expert Opinion on Drug Metabolism & Toxicology
Kaat HebbrechtBernard G C Sabbe

Abstract

Bipolar disorder is a severe, chronic psychiatric disorder with a need for long-term treatment. Patient nonadherence is frequent and poses a major problem in maintenance therapy. Aripiprazole once-monthly long-acting injectable (AOM LAI) is a recently US Food and Drug Administration-approved treatment option for maintenance therapy that could be of great value. Areas covered: This paper reviews the pharmacokinetic, efficacy and safety data for AOM LAI in bipolar disorder. Expert opinion: AOM LAI is a safe and efficacious treatment option in the maintenance therapy of bipolar I disorder. However, further research is still needed to determine the position of AOM LAI relative to other available treatment options.

References

Jan 22, 1998·Archives of General Psychiatry·S M StrakowskiM L Bourne
Apr 10, 2002·Acta Psychiatrica Scandinavica·Ravi Lingam, Jan Scott
May 22, 2002·The Journal of Clinical Psychiatry·Jan Scott, Marie Pope
Aug 29, 2003·The American Journal of Psychiatry·Paul E KeckUNKNOWN Aripiprazole Study Group
Nov 25, 2003·The Journal of Clinical Psychiatry·Joseph R CalabreseUNKNOWN Lamictal 605 Study Group
Jan 30, 2004·Journal of Clinical Pharmacology·Suresh MallikaarjunSteven L Bramer
Nov 24, 2004·The Journal of Clinical Psychiatry·Joseph R CalabreseMichael L Reed
Dec 14, 2004·CNS Drug Reviews·Marilyn A DaviesBryan L Roth
Dec 17, 2004·Journal of Clinical Pharmacology·Leslie CitromeSuresh Mallikaarjun
Jan 27, 2005·The Journal of Clinical Psychiatry·Molly M ShoresDaniel R Kivlahan
Oct 18, 2005·Bipolar Disorders·F ColomJ Scott
May 4, 2006·The Journal of Clinical Psychiatry·Paul E KeckUNKNOWN Aripiprazole Study Group
Oct 18, 2006·Bipolar Disorders·Ana Gonzalez-PintoRoss J Baldessarini
Oct 27, 2007·The Journal of Clinical Psychiatry·Paul E KeckUNKNOWN Aripiprazole Study Group
Jul 10, 2008·Clinical Pharmacokinetics·Suresh MallikaarjunSteven L Bramer
Nov 17, 2009·Current Pharmaceutical Design·Richard B Mailman, Vishakantha Murthy
Feb 4, 2010·The Journal of Clinical Psychiatry·Allan H YoungUNKNOWN EMBOLDEN I (Trial 001) Investigators
Mar 17, 2010·Biological Psychiatry·Jorge A QuirozVivek Kusumakar
Dec 31, 2010·The Journal of Clinical Psychiatry·Marion Leboyer, David J Kupfer
Mar 9, 2011·Archives of General Psychiatry·Kathleen R MerikangasZahari Zarkov
Mar 10, 2012·The Journal of Clinical Psychiatry·Michael E Thase
Sep 5, 2012·Journal of Clinical Pharmacy and Therapeutics·D W BoultonD M Kornhauser
May 15, 2013·Lancet·John R Geddes, David J Miklowitz
May 9, 2014·JAMA Psychiatry·Carsten Bøcker PedersenWilliam W Eaton
Sep 27, 2014·BMJ : British Medical Journal·Tim KendallUNKNOWN Guideline Development Group of the National Institute for Health and Care Excellence
Sep 22, 2015·Lancet·Iria GrandeEduard Vieta
Feb 13, 2016·Expert Opinion on Pharmacotherapy·Steven G Potkin, Adrian Preda
Aug 16, 2016·The American Journal of Psychiatry·Rodrigo Machado-VieiraCarlos A Zarate
Jan 13, 2017·World Journal of Psychiatry·Subho Chakrabarti

❮ Previous
Next ❯

Citations

May 11, 2019·Expert Opinion on Drug Safety·Alessandro CuomoAndrea Fagiolini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.